Trial intelligence / Profile preview

PRV111 in Oral Squamous Cell Carcinoma

NCT03502148Phase 2Completed

Sponsor
Privo Technologies, Inc.
Start
Jun 2018
Primary completion
Oct 2019
Modality
Nanoparticles
Countries
1
01

Overview

A Phase 2 trial of PRV111 in oral squamous cell carcinoma (OSCC), sponsored by Privo Technologies, Inc.. Started Jun 2018; status: completed.

02

Drugs

PRV111
03

Conditions

oral squamous cell carcinoma (OSCC)

Beyond the preview

Go deeper on NCT03502148.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03502148.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call